Tag Archives: HEA

PR Newswire

Hyland Healthcare Commended by Frost & Sullivan for Creating a New Standard in PACS Technology by Expediting Fully Informed Care Decisions

Leave a comment

Leveraging previously unstructured content via integration with EMRs, Hyland delivers a complete patient view for improved clinical decision-making and higher quality care

SANTA CLARA, Calif., Sept. 9, 2020 — Based on its recent analysis of the North American enterprise imaging solutions market, Frost & Sullivan recognizes Hyland Healthcare with the 2020 North America Product Leadership Award. By overcoming traditional information silos between departments and information formats, the company has set a new standard for managing, viewing, and exchanging both digital imaging and communications in medicine (DICOM) and non-DICOM records as well as data across an enterprise. Its full suite of content services and enterprise imaging solutions brings together structured and unstructured content into a single, comprehensive, and customizable view.

Hyland Healthcare
Hyland Healthcare

Hyland optimizes and streamlines data collection, transfer, and visualization, empowering healthcare enterprises to improve workflows and maximize reimbursements. Its extensive platform enables electronic medical record (EMR) integration of previously siloed information regardless of format, which is an unmatched offering within the industry. The solutions support all modalities for data and image viewing, including two-dimensional and three-dimensional visualization and tools, multi-linear reconstruction, PET-CT fusion, PET-MR fusion, computed tomography, MammoCAD, and structured reports. Furthermore, its products are vendor-neutral, which frees healthcare organizations to choose specific solutions and integrate them with existing systems.

"Hyland’s solutions leverage advanced custom application programming interfaces and context switching, incorporating them as part of an enterprise’s full solution to integrate with other vendor offerings, elegantly bridging the gap between imaging and content," said Dr. Suresh Kuppuswamy, Industry Principal at Frost & Sullivan. "Clinicians can make more informed care decisions as they have access to the patient’s complete medical record. The viewer integrates and displays both content and enterprise imaging information regardless of DICOM and non-DICOM formats within the healthcare organization’s EMR."

The company’s spectrum of solutions includes Acuo, a best-in-class universal archive to meet clinical and diagnostic viewing needs. Acuo creates a new viewing standard due to its unique interoperability, functionality, scalability, technical frameworks, and integration profiles. Meanwhile, the company’s web-based, zero-footprint, FDA-cleared enterprise and diagnostic viewer, NilRead, is built with differentiated and modern architecture for display on any device or browser platform. Other prominent solutions include ImageNext, an enterprise-wide workflow optimization tool, and PACSgear, a suite of enterprise-class connectivity solutions that allow users to capture vital encounter-based images and videos easily as well as documents and integrate them with a PACS or EMR.

"Hyland is currently investing in and working with international partners to develop a digital pathology solution that incorporates its zero-footprint NilRead enterprise and diagnostic viewer and Acuo VNA. Anticipating the future, it also designed its products to be cloud-based," noted Dr. Kuppuswamy. "As a result of its unmatched ability to enable enterprise-wide content viewing, more than 50% of the United States hospital market employs its solutions. The company is all set to expand further in the European Union, Asia-Pacific, Latin America, and Africa to entrench itself as a global market player."

Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com

Photo – https://techent.tv/wp-content/uploads/2020/09/hyland-healthcare-commended-by-frost-sullivan-for-creating-a-new-standard-in-pacs-technology-by-expediting-fully-informed-care-decisions.jpg

Related Links :

Frost New Home page v2

PR Newswire

Infosys to Acquire Product Design and Development firm, Kaleidoscope Innovation

Leave a comment

Expands engineering services portfolio by strengthening presence in Medical devices, Consumer and Industrial markets across US

BENGALURU, India and CINCINNATI, Sept. 4, 2020 — Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced a definitive agreement to acquire Kaleidoscope Innovation, a full-spectrum product design, development and insights firm innovating across medical, consumer and industrial markets, bolstering capabilities in the design of smart products. This acquisition demonstrates Infosys’ commitment to innovate for its clients, and make a meaningful impact on human lives by combining cutting-edge technologies and experiences to revolutionize patient care, treatment, diagnostics and consumer health across the world.

Kaleidoscope Innovation brings to Infosys a diverse talent pool with extensive knowledge of design and engineering. The company leverages a deep understanding of clinical environments, strong product development capabilities across domains, and a consultancy-style approach addressing human factors, product design, UI/UX design, research & insight, development and visualization. It serves a marquee and diversified customer base with state of the art, in-house labs, 3D design environments and customer experience centers. Kaleidoscope designs microsurgical instruments, devices used in minimally invasive surgery, drug delivery devices for ophthalmic therapies and user-centric wearables. It also offers usability testing in support of regulatory submissions, including the delivery mechanism for aortic stents.

Ravi Kumar, President, Infosys, said, "This acquisition further strengthens our digital offerings at the intersection of new software technologies and medical devices – a sector that is expected to witness significant investments and consumerization in the post-COVID era. Our clients will benefit from the combination of Kaleidoscope’s strong upstream offerings of product innovation and design, and Infosys’ stack of product engineering, validation and commercialisation services at a global scale. We are excited to welcome Kaleidoscope Innovation and its leadership team into the Infosys family, as part of Infosys Engineering Services portfolio."

Nitesh Bansal, SVP & Global Head of Engineering, Infosys, said, "Device engineering for both the consumer and medical industries has been a critical success parameter for our clients. The addition of upstream concept design and human factors engineering, through this acquisition not only provides us end-to-end capability, but also creates an engagement engine dedicated towards innovation and growth in this sector."

Matt Kornau, CEO & Co-Founder, Kaleidoscope Innovation said, "We are enthusiastic about our exciting new partnership with Infosys. It allows us to scale quickly and bring expanded offerings in AI, Analytics, and Digital Infrastructure to our clients. Kaleidoscope has always valued the ability to enhance people’s lives and their outcomes through innovation. We feel Infosys shares these same values and will open new avenues for our client partners, and our staff, to pursue larger opportunities together.  We will remain dedicated to serving as good partners to other companies, large and small, as we continue to meet our mission."

Bill Taylor, Co-Founder, Kaleidoscope Innovation added, "Infosys provides an exciting platform for us to extend our relationship with our Business Partners to address the productization of solutions they have been asking us to deliver. Having the technical prowess and bandwidth to offer solutions that address manufacturability and lifecycle management will benefit all parties. We can now offer them the scale needed for both front end innovation and back end implementation and sustainability"

The acquisition is expected to close during the second quarter of fiscal 2021, subject to customary closing conditions.

About Kaleidoscope Innovation

Kaleidoscope Innovation is a full-service product development firm innovating across medical, consumer and industrial markets. For over 30 years, clients have partnered with Kaleidoscope to improve the human experience. Kaleidoscope offers both consultancy-style and onsite services, across a full breadth of disciplines to meet their client’s needs where needed, including insights & human factors, medical affairs, industrial design & user experience, engineering, visualization and software development. For more information about Kaleidoscope Innovation, please visit www.kascope.com

About Infosys

Infosys is a global leader in next-generation digital services and consulting. We enable clients in 46 countries to navigate their digital transformation. With nearly four decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.

Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next.

Safe Harbor

Certain statements in this release concerning our future growth prospects, financial expectations and plans for navigating the COVID-19 impact on our employees, clients and stakeholders are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding COVID-19 and the effects of government and other measures seeking to contain its spread, risks related to an economic downturn or recession in India, the United States and other countries around the world, changes in political, business, and economic conditions, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our industry and the outcome of pending litigation and government investigation. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2020. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

Logo: https://mma.prnasia.com/media2/633365/Infosys_Logo.jpg?p=medium600

PR Newswire

As More Seniors Look to Age Independently, TCL Unveils the MOVETIME Family Watch to Help Keep Seniors Connected

Leave a comment

BERLIN, Sept. 3, 2020 — TCL, one of the world’s best-selling consumer electronics brands and leading technology companies, is introducing the MOVETIME Family Watch MT43A today. This 4G connected watch provides hands-free two way calling, automatic fall detection, heart rate monitoring and medication reminders designed to help seniors maintain their independence.

TCL MOVETIME Family Watch MT43A
TCL MOVETIME Family Watch MT43A

According to Pew Research, nearly 20 percent of seniors around the world live alone. While older adults may want to age in their homes and retain their independence, their loved ones may have concerns about their safety or their ability to get around and complete daily activities. The MOVETIME Family Watch MT43A is the perfect solution.

This watch provides automatic fall detection, which notes when the wearer falls and sends an immediate alert (within 60 seconds) to assigned emergency contacts with the individual’s precise location. The wearer can also dismiss the alert if necessary. With an embedded heart rate monitor and sensor, the watch will also keep an eye on heart rate and will alert the wearer to irregular activity, such as an accelerated or slower than average heart rate.

"With the announcement of the MOVETIME Family Watch MT43A, TCL is utilizing modern wearable technologies that can help seniors continue living independent lives while providing peace of mind for their families and caregivers," said Sharon Xiao, GM of the Smart Connected Device Business Group at TCL Communication. "TCL is committed to leveraging its technical expertise for this generation, bringing unique offerings and features that are designed especially for them." 

In addition to medical emergencies, the MOVETIME Family Watch MT43A is also designed to improve daily life for older adults. Seniors stay connected by sending voice or text messages and can also share photos or emojis right from their wrist. The watch also offers smooth two-way calling so seniors can check in with loved ones using a simple hands-free request. The MOVETIME Family Watch also has daily activity tracking and sleep monitoring to help the seniors track their activity and calories, while also measuring their sleep duration, cycle and efficiency. These tools provide them with insights that can help improve their lifestyle habits. Seniors can also leverage the watch’s medication or activity reminders, keeping them active while also making sure that they always take their pills on time.

The MOVETIME Family Watch MT43A comes in Dark Gray and Black with a 41 x 48.5mm AMOLED touch display and optimized larger icons, watch face and graphics designed for seniors. The device is IP67 water and dust resistant and it is designed to meet CCPA and GDPR compliance to protect user privacy. The MOVETIME Family Watch MT43A will be available in North America and Europe this fall for €229 EUR.

TCL will share additional details during its virtual press conference at IFA 2020 later today. To learn more about TCL wearables, including the TCL MOVETIME Family Watch, please visit http://www.tclcom.com/wearables/index.html.

About TCL Electronics

TCL Electronics (1070.HK) is one of the world’s fastest-growing consumer electronics companies and one of the world’s leading television and mobile device manufacturers. For nearly 40 years TCL has operated its own manufacturing and R&D centers worldwide, with products sold in more than 160 countries throughout North America, Latin America, Europe, the Middle East, Africa and Asia Pacific. TCL specializes in the research, development and manufacturing of consumer electronics ranging from TVs, mobile phones, audio devices and smart home products as part of the company’s "AI x IoT" strategy. For more information on TCL mobile devices, please visit: http://www.tcl.com/global/en.html.

Related Links :

http://www.tcl.com/global/en.html

PR Newswire

Jvion Lauded by Frost & Sullivan for Improving Patient Outcomes Using Its Clinical-AI CORE™ Intelligence Platform

Leave a comment

Jvion’s prescriptive analytics approach identifies undetected risk and modifiable risk trajectories followed by recommendations for remedial actions

SANTA CLARA, California, Sept. 1, 2020 — Based on its recent analysis of the North American prescriptive analytics market, Frost & Sullivan recognizes Jvion, Inc. with the 2020 North American Technology Innovation Leadership Award for its clinical-AI Care Optimization and Recommendation Enhancement (CORE™) technology. It is a scalable, secure intelligence repository that aggregates structured as well as unstructured data and augments that information with clinical, socioeconomic, and experiential data on 30 million individuals to draw meaningful correlations and inferences. To date, Jvion’s clinical AI has helped more than 300 hospitals, payers, and pharmacy managers achieve 30 percent reductions in preventable adverse incidents, which translate to annual savings of more than $6.3 million.

2020 North American Prescriptive Analytics Technology Innovation Leadership Award
2020 North American Prescriptive Analytics Technology Innovation Leadership Award

"The CORE™ identifies health and financial risk trajectories that can be modified, delivers prioritized insights to the care teams and coordinators engaging patients, and makes recommendations to improve outcomes. As a prescriptive analytics solution, it can proactively mitigate preventable harm that could otherwise lead to hospital readmissions, serious conditions, or accelerated health deterioration," said Cecilia Van Cauwenberghe, Industry Principal. "With this first-in-class AI platform, Jvion evolved from a provider of simple predictive analytics and machine learning solutions to a technology leader that can help identify potentially high-risk patients and suggest specific remedial action."

The solution leverages a combination of Eigen-based mathematics, datasets from over 30 million patients, and a software platform to promptly act upon 50+ preventable clinical events, covering behavioral health, hospital acquired conditions, chronic conditions, hospice/palliative care, and medication adherence. Additionally, it can identify avoidable cost events including uncompensated care and help customers work with their patient population to identify the right financial assistance. Importantly, the CORE™ does not require the creation of new models or perfect datasets. The underlying AI capability assesses 4,500 clinical and non-clinical risk factors for every patient and a quadrillion risk calculations through 170,000 self-learning Eigen Spheres clusters in real-time.

Frequently used enterprise data warehouse or data lake models demand considerable resources just to deliver a retrospective view of the patient’s health risk. Similarly, scoring methods such as LACE and BRADEN do not provide enough granularity or patient specificity to determine all the factors impacting the patient’s health. Jvion’s CORE™, on the other hand, boasts patient specificity, high effectiveness (seven times more effective than popular scoring methods), patient rendering (up to 365 days view into the future), successful use of even incomplete and unstructured datasets, and the fastest speed to value. Each of these benefits helps deliver effective, personalized patient care.

"As a result of its patient-centric approach to understanding vulnerability and risk, Jvion was able to pivot quickly during a pandemic to launch its COVID Response Suite, which delivers lists of individuals most vulnerable to severe illness. These insights enable proactive and targeted outreach to individuals that need to take more aggressive precautions," noted Cauwenberghe. "The relevance of its solutions, along with its patient-focused technology development efforts, has positioned Jvion for accelerated growth."

"Jvion is honored to be recognized for executing on its mission of preventing avoidable harm whether categorized as a health or financial event for our customers," said Jay Deady, CEO of Jvion. "Our team is constantly innovating to ensure our prescriptive AI approach is relevant to the changing dynamics of the healthcare industry."

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies that deliver significant customer value.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Harley Gadomski
P: 12104778469
E: harley.gadomski@frost.com

About Jvion, Inc.

Jvion, a leader in clinical artificial intelligence, enables providers, payers and other healthcare entities to identify and prevent avoidable patient harm, utilization and costs. An industry first, the Jvion CORE™ goes beyond predictive analytics and machine learning to identify patients on a trajectory to becoming high-risk. Jvion then determines the interventions that will more effectively reduce risk and enable clinical and operational action. The CORE accelerates time to value by leveraging established patient-level intelligence to drive engagement across healthcare organizations, populations, and individuals. To date, the Jvion CORE has been deployed across hundreds of clients and resulted in millions saved. For more information, visit http://www.jvion.com.

Media Contact:

Anya Nelson
Scratch Marketing + Media for Jvion
anyan@scratchmm.com 
617.817.6559

 

Related Links :

Frost New Home page v2

PR Newswire

GEN inCode Announces Completion of £3M Institutional Foundation Fundraise

Leave a comment

OXFORD, England, Sept. 1, 2020 — GEN inCode UK Limited, the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the completion of a £3.0M institutional fundraise to internationally scale its products and technology.   

GEN inCode specializes in genetic risk assessment and the prediction of cardiovascular disease. Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease, such as angina and myocardial infarction, often referred to as "heart attack". CVD also includes stroke, heart failure, hypertension, venous thromboembolism and other vascular heart diseases. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. By 2030, the total global cost of CVD is set to rise from approximately US $863 billion in 2010 to US $1,044 billion and is both a major health issue and global economic burden.

GEN inCode’s CE marked invitro-diagnostic products provide genetic information to enable patients, doctors and healthcare practitioners to assess and predict the onset of CVD. The Company’s products and ‘cloud-based’ reporting system help inform healthcare practitioners and patients of their CVD risk, enabling behavioural change alongside delivery of the most effective course of treatment. 

GEN inCode has amassed significant investment in over 15 years’ worth of research data and the development of products and algorithms to assess disease risk and prevent the onset of CVD. In September 2018, the Company acquired the products, assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, then part of The Ferrer Group, a large pharmaceutical and healthcare multinational company with headquarters in Barcelona, Spain. GEN inCode has now received institutional funding from Maven Capital Partners and Downing to expand its operations in Europe, the UK and U.S.

GEN inCode’s vision is to educate patients about their cardiovascular risk and to improve public health by using the predictive capability of its products with targeted therapies to determine lifestyle choice and improve patient outcomes.

Matthew Walls, Chairman and CEO, said: "We are delighted to complete the institutional round of funding and welcome Maven and Downing, our new institutional investors. The funding will prepare the Company for accelerated growth and international scale and supports our regulatory and clinical pathway into the U.S. market. We look forward to advising the market on our progress and further milestones in due course."

Jordi Puig, Co-founder and Group COO, said: "This marks another milestone in the development of our Company and prepares us to rapidly scale our products and technology across our European business."

Enquiries:

GEN inCode UK Limited

Matthew Walls

Tel +44 (0)7887 501998  

www.genincode.com

About GEN inCode:

GEN inCode is a UK-based company specializing in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide.

GEN inCode UK Limited operates business units in Europe and Latin America through GEN inCode S.L.U., and in the United States through GEN inCode U.S. Inc.

GEN inCode’s predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our CE marked invitro-diagnostic molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset.

PR Newswire

G-ray Switzerland announces new CEO, closes successful funding round

Leave a comment

NEUCHÂTEL, Switzerland, Aug. 31, 2020 — G-ray Switzerland, the medical imaging and industrial diagnosis start-up founded in 2014, has announced the appointment of Luis Pallares as Chief Executive Officer, as the company embarks on an accelerated growth drive and completes a successful funding round.

Mr Pallares is focused on leading the transformation of G-ray’s business development efforts following the company’s development of a disruptive and patented state of the art technology to bring safer, cheaper and better vision into imaging for medical and industrial diagnosis.

Mr Pallares joins G-ray with a wealth of entrepreneurial and start-up experience, having founded Spain’s first streaming service, Addhoc Streaming, Spanish-speaking health related content site Vivir Mejor, and Spain’s leading digital strategy firm, Nennisiwok.

Most recently Mr Pallares’ deep experience in technology development, artificial intelligence and digital advertising led him found Plyzer Technologies, a global leader of price comparison technology matched with business analytics and intelligence based on artificial intelligence.

The appointment coincides with the news that G-ray has also raised a further CHF 2.6 millions, enabling it close out its successful Series A funding round at CHF 28 million.

Luis Pallares, Chief Executive Officer of G-ray, said: "G-ray has already proven to be a positive disruptive force within the technology industry and I relish the opportunity to help deliver tangible progress by bringing improvements in imaging into medical and industrial diagnosis."

Mr Yves Claude Aubert, Chairman of G-ray Switzerland, said: "Our technology has already started to disrupt the multi-billion particle detection imaging markets, based on our proprietary and transformative unique detector architecture. As artificial intelligence impacts the traditional X ray detector market, Luis is the perfect choice to lead G-ray forward into a new phase of growth and to capture these opportunities.

About G-ray Switzerland

Founded in 2014 in Neuchâtel, G-ray Switzerland SA has filed a number of revolutionary patents in the fields of radiographic imaging and new semiconductor assembly techniques. The rapidly expanding company has developed core skills in monolithic detectors with integrated high-resolution CMOS circuits. These innovations cover a wide range of sectors, including automotive, aerospace and medicine. www.g-ray.ch

 

 

Related Links :

http://www.g-ray.ch

PR Newswire

First Rapid Corona Antigen Test Approved for Clinical Study in Germany

Leave a comment

The health tech company Digital Diagnostics AG from Mainz, Germany, has received approval for clinical trials from a German ethics committee and the Federal Institute for Drugs and Medical Devices (BfArM). This is a crucial regulatory step in the ongoing approval process for the Digid Cantisense™ SARS-CoV-2 test in Germany. The aim of the clinical trials is to demonstrate the reliability of the new technology in comparison with conventional PCR tests. The new test is particularly suitable for access control at airports or at large-scale event

MAINZ, Germany, Aug. 26, 2020 — In June 2020, the health technology company Digital Diagnostics AG from Mainz, applied for approval of the Digid Cantisense™ SARS-CoV-2 test for Germany at the German Federal Institute for Drugs and Medical Devices (BfArM). BfArM has now permitted the conduct of clinical trials in accordance with Section 20 (1) of the German Medical Devices Act (MPG). Meanwhile, the ethics committee of the Rheinland-Pfalz Medical Association (Landesärztekammer) has also given a positive vote.

Completion of the clinical evaluation of the Digid biosensor and the accompanying reading device is expected in October 2020. If the results meet expectations, the rapid Cantisense™ test shall be approved in short succession. Digital Diagnostics AG will then be able to launch the tests on the market in millions. The company currently develops the necessary production capacities, ready for use in time right after the approval.

The leading center to carry out the clinical trials is PFÜTZNER Science & Health Institute in Mainz, which works closely with scientists and MDs from corona test centers and clinics throughout Germany. It is planned to perform the study locally as well as in known German corona hotspots.

In the study, patients are tested in parallel with a standard PCR method and with the Digid Cantisense™ SARS-CoV-2 test. Like with all common SARS-CoV-2 determinations, medical staff takes a throat swab from the patient. The sample is analyzed directly on site with the Digid rapid test system and afterwards compared with the result of a PCR test from a reference laboratory to demonstrate the accuracy of the Digid Cantisense™ SARS-CoV-2 test. The design of the study complies with FDA and EU Commission guidelines for in-vitro measurement procedures to detect SARS-CoV-2.

One key advantage of the Digid Cantisense™ SARS-CoV-2 test is that it directly detects the presence of the virus in the sample, while other available rapid tests mostly detect antibodies. Patients only develop these antibodies if they have had an infection for several days, a time during which they were contagious and might unknowingly have infected others. With the unique combination of immediate on-site detection of the virus in tested patients, the Digid Cantisense™ SARS-CoV-2 test is particularly useful to contain the spread of the pandemic and suitable for on-site access control and rapid testing, for example at airports, in hospitals or at large-scale events.

Press contact

Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
digid-pr@semanticom.eu

Related Links

Medium

Website

Related Links :

digid GmbH
PR Newswire

Clarivate Launches Coronavirus, Virology, and Infectious Disease (CVID) Data Lake to Accelerate Research, Preparedness and Response to Future Pandemics

Leave a comment

Broad and deep intelligence — harmonized and accessed via one single, secure source — powers unique insights not possible via disconnected, siloed datasets

LONDON, Aug. 20, 2020 — Clarivate Plc (NYSE: CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of its Coronavirus, Virology, and Infectious Disease (CVID) Data Lake to support global researchers and policy makers in their efforts to make data-driven decisions that accelerate disease response, prevent and prepare for future pandemics.

The CVID Data Lake is the first of several therapeutically-oriented data lakes from Clarivate, bringing together the comprehensive information and insights that power the company’s market-leading tools, analytics and services, including real-world data (RWD) from DRG’s RWD product; scientific, clinical, regulatory and commercial data from Cortellis™; cited scholarly references indexed in Web of Science™; and both content and data from award-winning news service, BioWorld™, in one centralized source.  Data from other sources can also be integrated, further enhancing derived insights.

During these unprecedented times, researchers and policy makers need to connect the dots across multiple data points. Collaboration across public and private networks is integral to solving the current health crises and preventing future ones. The CVID Data Lake is a uniquely unified dataset focused on the coronaviruses, including COVID-19, as well as virology, super viruses and infectious diseases, enabling researchers to mine and interrogate harmonized data from a single, expertly curated source and access complete, structured and connected data to enable fact and evidence-based decisions. 

Ken McLaren, SVP and GM, Data Analytics & Insights (DAI) at Clarivate, said: "The new imperative for global health requires researchers and policy makers to accelerate their efforts to both treat and prevent future pandemics and infectious diseases.  A unified data set allows for more complex analyses and improved insights not efficiently available through disparate, siloed databases. With our new Coronavirus, Virology, and Infectious Disease Data Lake, researchers around the world can access scientific, clinical, commercial and research data within one seamless and secure platform." 

Now, more than ever, pharma and biotech companies are interested in understanding the disease impact on clinical trials and treatment patterns, monitoring how research funding and the regulatory landscape is evolving in response to COVID-19, optimizing the use of biomedical R&D and manufacturing resources, and developing global strategies to support pricing, market access and reimbursement in areas of interest.

Government agencies are looking to measure the impact of infectious disease on the capacity of the healthcare system and essential supplies, analyze how the health policy, research and regulatory landscape is changing in response to COVID-19, and develop pricing and reimbursement policies to ensure access to medicines.  The insights derived from the CVID Data Lake support these use cases and more – providing unprecedented decision support and planning inputs while serving as a bridge between policy and practice and enabling improved use of resources across the public-private continuum.

The CVID Data Lake features all related content in one place, connected in new ways, supporting a multitude of end users, to enable deeper insights and delivery of complex and high value use cases.  Clients can choose from an array of delivery options depending on their resource needs and expertise, including: datasets and programmatic access; preconfigured dashboards, reports or customized tools; custom analytics based on specific requirements; or consulting engagements that include analysis and recommendations.

The CVID Data Lake includes: real-world patient data; drug pipeline data; genes and targets; clinical trials; digital health data; publication and citation data; epidemiology; regulatory intelligence; patents and more.  Other therapy areas will be launched to help researchers accelerate innovation in other therapeutic areas. The new offering further demonstrates how the combined expertise, data and technologies of Clarivate and DRG, which was acquired by Clarivate earlier this year, can support customers across the entire drug, device and medical technology lifecycles.

To learn more about the CVID Data Lake, visit http://www.clarivate.com/cvidlake.

ENDS

About Clarivate
Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we’re setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world’s most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information please visit www.Clarivate.com.

Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate. Forward-looking statements provide Clarivate’s current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate’s control that may cause actual results to differ materially. Clarivate undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

Logo – https://mma.prnasia.com/media2/1159266/Clarivate_Analytics.jpg?p=medium600

Related Links :

http://www.Clarivate.com

PR Newswire

South Korea’s KT Develops AI-Based COVID-19 Research

Leave a comment

– Korean Telecom Leader’s Proposal Accepted by Global Research Fund –

– KT’s AI, Big Data and Medical Resources Enhances Risk Assessment –

– New Project to Help KT Develop Global Epidemic Prevention Platform –

SEOUL, South Korea, Aug. 20, 2020 — KT Corp. (KRX: 030200; NYSE: KT), South Korea’s largest telecommunications company, is developing a COVID-19 infection risk assessment model, using its artificial intelligence (AI) and Big Data-based digital contact tracing technology, adding to global efforts to tackle the escalating pandemic.

The Korean telecom leader’s new pilot project is supported by the Research Investment for Global Health Technology Fund, better known as RIGHT Fund. The global research fund accepted the promising proposal by KT to develop AI-based technology that assesses COVID-19 infection risks.

"KT’s new project will help combat the pandemic globally," said Kim Chae-Hee, head of KT’s AI/Big Data division. "We at KT will do our best to help prevent COVID-19 from further spreading and raise the efficacy of medical service, using our AI and Big Data technologies for the sake of humanity."

KT plans to use the pilot project results to apply for a larger-scale, RIGHT Fund-supported project in 2021. RIGHT Fund is a global health research funding agency established in 2018 with contributions from Korea’s Ministry of Health and Welfare, the Bill & Melinda Gates Foundation and Korean life science companies to promote global public health.

For the pilot project, KT plans to assess COVID-19 infection risks by using AI and Big Data to analyze data on the movement of smartphone users and those who have been tested positive for COVID-19 and made public by the government.

"KT’s project will help developing countries, which are faced with shortages of medical resource, prevent the pandemic from spreading and conduct appropriate examinations and treatments," said Kim Youn-Been, CEO of the RIGHT Fund. "We hope that the project, taking advantage of Korea’s advanced expertise in ICT, will be carried out successfully to support developing countries in preventing, treating and managing the COVID-19 pandemic."

Mobile Doctor Corp. is also participating in this project, which is scheduled to end in February 2021. Both KT and Mobile Doctor, a provider of data-based platforms and solutions for health management, are members of a consortium conducting "A Next Generation Surveillance Study for Epidemic Preparedness," a three-year research program financed by the Bill & Melinda Gates Foundation.

KT expects the assessment model, based on identification of those who have been exposed to carriers of the novel coronavirus directly and indirectly, will help prevent further transmission of the COVID-19 pandemic while minimizing the risk of personal information leakage.

Korea’s top telecom company also looks forward to acquiring the capabilities to identify vulnerable high-risk groups in case of a second wave of the pandemic or group infections, and promote an effective use of limited medical resources, such as medical personnel and test kits.

Through the research, KT plans to further upgrade its Global Epidemic Prevention Platform (GEPP), focusing on providing information on infection risks of contagious diseases and digital contact tracing. GEPP uses Big Data and social media to give updates to travelers going to countries hit by epidemics and to track the movement of infected individuals.

At the same time, KT will help reduce the gap in the provision of medical service among different regions and different income groups in underdeveloped countries, using its information communication technology and digital capacity for research and development on health.

Eight South Korean life science companies donated to the RIGHT Fund. The fund is dedicated to addressing inequalities in health between regions and income groups around the world, through research and development for vaccines, therapeutics, diagnostics and digital health technologies, taking advantage of Korea’s advanced R&D capabilities.

##### End #####

MEDIA CONTACTS

For inquiries, please contact our Foreign Media Relations Team at kt.fmrt@gmail.com

ABOUT KT CORPORATION (KRX: 030200; NYSE: KT)

KT Corp., Korea’s largest telecommunications service provider, reestablished in 1981 under the Telecommunications Business Act, is leading the era of innovations in the world’s most connected country. The company is leading the 4th industrial revolution with high speed wire/wireless network and new ICT technology. KT launched the world’s first nationwide commercial 5G network on April 3, 2019, after successfully showcasing the world’s first trial 5G services at the PyeongChang Winter Olympic Games in February 2018. This is another milestone in KT’s continuous efforts to deliver essential products and services as it aspires to be the number one ICT Company and People’s Company.

For more information, please visit our English website at https://corp.kt.com/eng/

Related Links :

https://corp.kt.com/eng/

PR Newswire

Hong Kong’s Hang Fook Elderly Home Adopts iBonus(R) Digital Prevention System Aimed at Helping Guard Against COVID-19

Leave a comment

The new iBonus® Digital Prevention System is being adopted by a growing number of businesses, companies, and other entities in Hong Kong in an effort to help break COVID-19 transmission chains.

HONG KONG, Aug. 20, 2020 — One of the key reasons that COVID-19 has caused a great concern is its long incubation period. Most experts agree that for up to 14 days many affected patients have no obvious symptoms. Since nobody knows where these people have been or who they have been in contact with in the incubation period, many people around them could potentially also be infected, leading to eruptions of infection in communities and large numbers of new cases. Masks and glove can help stop this but there is clearly a demand for other safeguards as well. To help solve this problem, Hong Kong technology company iBonus Limited has launched a digital prevention system that records the times and places participants have visited through employee smart cards, or the Octopus transit card and a set of designated terminals installed at different locations.

Once someone’s infection has been confirmed, the system will immediately enter all persons who have appeared at the same times and places with the confirmed patient in the past 14 days into an alert list and the list will be sent to all terminals. When someone on the list enters an area, the terminal at that area will ring an alarm.

"COVID-19 has scared so many people because confirmed patients show no obvious symptoms during the incubation period," commented Keith, Managing Director of iBonus Limited. "As a result, they move around in the community like invisible people. If a system can track these patients as well as those in close contacts with them during the incubation period and restrict them from entering high-risk venues such as fresh markets, the elderly homes, hotpot and other restaurants, it can help to cut the chain of transmission and, we hope, put the pandemic under greater control."

The company understands that other kinds of technology working in this area, like contact trackers, have created understandable privacy concerns. Keith suggests the situation is different for this system as it only records the Octopus serial number, which is different from the real-name health code operation number recorded by competitors. By not attaching a real-name to the Octopus serial number it ensures there is no violation to participants’ privacy.

Currently, Hang Fook Elderly Home, Warwick Hotel, On Tai Fresh Market have adopted this system. iBonus is also in negotiation with many large restaurants and malls to also come onboard. Expect more news regarding these developments soon.

For more information be sure to visit https://covid2019system.com.

About iBonus Limited

iBonus Limited was incorporated on 9 June 2014. The iBonus® Legacy system is a contactless smartcard-based pre-paid offline system similar to the Hong Kong Octopus system.

Media Contact

Ms. Anna Lee
Telephone: (852) 91501890
Email: anna@iBonus.net